Literature DB >> 34196739

[71/f-Multiple vertebral body fractures and glucocorticoid treatment : Preparation for the medical specialist examination: part 74].

E Tsourdi1,2.   

Abstract

Entities:  

Year:  2021        PMID： 34196739     DOI： 10.1007/s00108-021-01072-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  9 in total

Review 1.  Osteoporosis treatment: recent developments and ongoing challenges.

Authors:  Sundeep Khosla; Lorenz C Hofbauer
Journal:  Lancet Diabetes Endocrinol       Date:  2017-07-07       Impact factor: 32.069

Review 2.  DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?

Authors:  Richard Eastell; Tom Pigott; Fatma Gossiel; Kim E Naylor; Jennifer S Walsh; Nicola F A Peel
Journal:  Eur J Endocrinol       Date:  2017-10-18       Impact factor: 6.664

Review 3.  Use of oral corticosteroids and risk of fractures.

Authors:  T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

4.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

5.  Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

Authors:  Kenneth G Saag; Jose R Zanchetta; Jean-Pierre Devogelaer; Robert A Adler; Richard Eastell; Kyoungah See; John H Krege; Kelly Krohn; Margaret R Warner
Journal:  Arthritis Rheum       Date:  2009-11

6.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.

Authors:  Kenneth G Saag; Jeffrey Petersen; Maria Luisa Brandi; Andrew C Karaplis; Mattias Lorentzon; Thierry Thomas; Judy Maddox; Michelle Fan; Paul D Meisner; Andreas Grauer
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245

7.  Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.

Authors:  Elena Tsourdi; M Carola Zillikens; Christian Meier; Jean-Jacques Body; Elena Gonzalez Rodriguez; Athanasios D Anastasilakis; Bo Abrahamsen; Eugene McCloskey; Lorenz C Hofbauer; Nuria Guañabens; Barbara Obermayer-Pietsch; Stuart H Ralston; Richard Eastell; Jessica Pepe; Andrea Palermo; Bente Langdahl
Journal:  J Clin Endocrinol Metab       Date:  2020-10-26       Impact factor: 5.958

Review 8.  Osteoporosis Treatment with Anti-Sclerostin Antibodies-Mechanisms of Action and Clinical Application.

Authors:  Martina Rauner; Hanna Taipaleenmäki; Elena Tsourdi; Elizabeth M Winter
Journal:  J Clin Med       Date:  2021-02-16       Impact factor: 4.241

9.  A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX.

Authors:  Eugene V McCloskey; Anders Odén; Nicholas C Harvey; William D Leslie; Didier Hans; Helena Johansson; Reinhard Barkmann; Stephanie Boutroy; Jacques Brown; Roland Chapurlat; Petra J M Elders; Yuki Fujita; Claus-C Glüer; David Goltzman; Masayuki Iki; Magnus Karlsson; Andreas Kindmark; Mark Kotowicz; Norio Kurumatani; Timothy Kwok; Oliver Lamy; Jason Leung; Kurt Lippuner; Östen Ljunggren; Mattias Lorentzon; Dan Mellström; Thomas Merlijn; Ling Oei; Claes Ohlsson; Julie A Pasco; Fernando Rivadeneira; Björn Rosengren; Elisabeth Sornay-Rendu; Pawel Szulc; Junko Tamaki; John A Kanis
Journal:  J Bone Miner Res       Date:  2015-11-19       Impact factor: 6.741
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.